Our findings revealed that SHP2 inhibition may represent a potential therapy in both BTZ naïve and resistant MM patients, and the combination treatment of SHP2 inhibitors with BTZ may be a promising therapeutic strategy for future clinical investigation. This evidence concerns the gene PTPN11 and Miyoshi myopathy.